Core Viewpoint - PwC announced its mid-term results for 2025, showing a revenue increase driven by strong sales in blood purification and the introduction of revenue from regenerative medical biomaterials, despite a decline in infusion device sales [1] Financial Performance - Revenue reached approximately 414 million, representing a year-on-year increase of 22.4% [1] - Profit attributable to shareholders was approximately 66 million, reflecting a year-on-year decrease of 6.0% [1] - Earnings per share were reported at 4.44 cents, with an interim dividend of 4.4 Hong Kong cents per share [1] Business Segments - The revenue growth was primarily attributed to robust sales in the blood purification business and the first-time revenue recognition from regenerative medical biomaterials [1] - The decline in net profit was mainly due to reduced operating profit and financial income [1]